| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/06/2006 | WO2006035203A1 Cancer combination therapy comprising azd2171 and imatinib |
| 04/06/2006 | WO2006035061A1 Hcv inhibiting bi-cyclic pyrimidines |
| 04/06/2006 | WO2006034873A1 METHODS FOR THE GENERATION OF HEPATOCYTE-LIKE CELLS FROM HUMAN BLASTOCYST-DERIVED STEM (hBs) |
| 04/06/2006 | WO2006034872A1 Substituted 2-anilinopyrimidines as cell cycle kinase inhibitors or receptor tyrosine kinase inhibitors, production of said substances and use of the latter as medicaments |
| 04/06/2006 | WO2006034849A1 Antitumoral pharmaceutical compositions comprising a spisulosine and a cyclodextrin |
| 04/06/2006 | WO2006034833A1 Cyclic diarly ureas suitable as tyrosine kinase inhibitors |
| 04/06/2006 | WO2006034797A1 Thermodynamically stable form of bay 43-9006 tosylate |
| 04/06/2006 | WO2006034789A1 Proline derivatives |
| 04/06/2006 | WO2006034567A1 Use of compositions comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions |
| 04/06/2006 | WO2006000753A3 Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer |
| 04/06/2006 | WO2005100373A3 Monosaccharide derivatives as anti-cancer and anti-inflammatory agents |
| 04/06/2006 | US20060074244 Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway |
| 04/06/2006 | US20060074230 Cartilage matrix protein fusion for use in prevention and treatment of diabetic retinopathy, edema, sepsis and blood disorders |
| 04/06/2006 | US20060074229 Monoclonal antibodies induce apoptosis |
| 04/06/2006 | US20060074125 Novel dithiolopyrrolones with therapeutic activity |
| 04/06/2006 | US20060074123 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/06/2006 | US20060074119 Thiophene compounds |
| 04/06/2006 | US20060074116 3-(Heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 04/06/2006 | US20060074113 Antitumor, anticancer agents; using a 2-amino-5-phenyl-(1,3,4)thiadiazoline compound |
| 04/06/2006 | US20060074112 N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors |
| 04/06/2006 | US20060074107 Pharmaceutically active piperidine derivatives |
| 04/06/2006 | US20060074096 anti-cell prolifertive agents; 4-(1,2-diethylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine; cancers, solid tumours, leukemias, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, hemangioma, nephropathies, atheroma, atherosclerosis, restenosis, autoimmune diseases, inflammation |
| 04/06/2006 | US20060074094 Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia |
| 04/06/2006 | US20060074092 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases |
| 04/06/2006 | US20060074078 Product comprising a transduction inhibitor of heterotrimeric G protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer |
| 04/06/2006 | US20060074044 Nucleotide sequences coding stem cell factors for use as therapeutic tools in treating learning and memory disorders |
| 04/06/2006 | US20060074038 Her-2 neu dna vaccine having anti-cancer activity |
| 04/06/2006 | US20060074027 Microcapsules of luteinizing hormone releasing hormone agonists; glycolic acid-lactic acid copolymers; for treating prostate cancer, prostatomegaly, endometriosis, hysteromyoma, metrofibroma, precocious puberty, dymenorrhea or breast cancer, or inhibiting conception |
| 04/06/2006 | US20060074008 monoclonal antibody conjugated with peptide drug such as dolastatin derivative |
| 04/06/2006 | US20060073479 Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness |
| 04/06/2006 | US20060073477 Altered DNA synthesome components as biomarkers for malignancy |
| 04/06/2006 | US20060073472 Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
| 04/06/2006 | US20060073333 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 04/06/2006 | US20060073223 Phloridzin-rich phenolic fraction and use thereof as a cosmetic, dietary or nutraceutical agent |
| 04/06/2006 | US20060073222 Saponin mixtures and compounds isolated from Acacia victoriae; glycosides of acacic or oleanolic acid; control of cell apoptosis and cytotoxicity; antitumor, -carcinogenic, -inflammatory and -proliferative agents; atherosclerosis |
| 04/06/2006 | US20060073166 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR |
| 04/06/2006 | US20060073162 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor |
| 04/06/2006 | US20060073150 monoclonal antibodies or antigen binding fragments that specifically to six transmembrane epithelial antigens of the prostate (STEAP-1), used for medical diagnosis, prognosis, prophylaxis and/or therapy for cancers |
| 04/06/2006 | US20060073146 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 04/06/2006 | US20060073140 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 04/06/2006 | US20060073125 Isolation and use of solid tumor stem cells |
| 04/06/2006 | US20060073123 Adenovirus vectors for immunotherapy |
| 04/06/2006 | US20060073114 Compounds and methods to inhibit or augment an inflammatory response |
| 04/06/2006 | US20060073100 Detection and therapy of vulnerable plaque with fluorescent and/or radiolabeled compositions |
| 04/06/2006 | DE10231370B4 Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel Thiophenglycosidderivate, pharmaceutical compositions containing them and methods for making these drugs |
| 04/06/2006 | DE102004054545A1 Änderung des Beladungszustandes von MHC-Molekülen Changing the load state of MHC molecules |
| 04/06/2006 | CA2583397A1 Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| 04/06/2006 | CA2582777A1 Proton pump inhibitors |
| 04/06/2006 | CA2581969A1 Telomelysin-gfp gene-containing recombinant virus |
| 04/06/2006 | CA2581737A1 Proline derivatives |
| 04/06/2006 | CA2581658A1 Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals |
| 04/06/2006 | CA2580953A1 Antitumor composition |
| 04/06/2006 | CA2580811A1 Carbostyril compound |
| 04/06/2006 | CA2580798A1 Methods for the generation of hepatocyte-like cells from human blastocyst-derived stem (hbs) |
| 04/06/2006 | CA2579612A1 Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof |
| 04/06/2006 | CA2579240A1 Small molecule modulators of cytokine activity |
| 04/06/2006 | CA2579067A1 Cancer combination therapy comprising azd2171 and imatinib |
| 04/06/2006 | CA2578956A1 Combination comprising zd6474 and an imatinib |
| 04/06/2006 | CA2577185A1 Cyclic diarly ureas suitable as tyrosine kinase inhibitors |
| 04/05/2006 | EP1642974A1 Recombinant soluble Fc receptors |
| 04/05/2006 | EP1642973A1 Therapeutic uses of BR43X2 soluble receptors |
| 04/05/2006 | EP1642972A1 Therapeutic uses of BR43X2 soluble receptors |
| 04/05/2006 | EP1642968A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642967A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642909A2 Serpentine transmembrane antigens expressed in human prostate cancers and uses thereof |
| 04/05/2006 | EP1642907A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642906A2 Composition and methods for the diagnosis of tumours |
| 04/05/2006 | EP1642888A1 compounds for modulating the rage receptor |
| 04/05/2006 | EP1642880A1 Hsp90 family protein inhibitors |
| 04/05/2006 | EP1642596A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 04/05/2006 | EP1642592A1 Remedy for sarcoidosis and method of treating the same |
| 04/05/2006 | EP1642591A1 MEDICINAL COMPOSITION CONTAINING NF-kAPPA B DECOY FOR TREATING AND PREVENTING RESPIRATORY DISEASES AND METHOD OF USING THE SAME |
| 04/05/2006 | EP1642587A1 Follicle-stimulating hormone releasing agent |
| 04/05/2006 | EP1642586A1 Cell-containing preparations |
| 04/05/2006 | EP1642575A1 Use of r-nsaid's for the prevention of alzheimer's disease |
| 04/05/2006 | EP1642574A2 Combination of a beta-2 adrenoceptor agonist and an aminosugar and their use for the treatment of immunomodulatory disorders |
| 04/05/2006 | EP1642133A2 In vitro methods for detecting renal cancer |
| 04/05/2006 | EP1641919A2 Applications of a new class of enzymes: sulfiredoxines |
| 04/05/2006 | EP1641824A1 Relaxin superfamily peptide analogues |
| 04/05/2006 | EP1641820A1 Rasgap derived peptide for selectively killing cancer cells |
| 04/05/2006 | EP1641818A1 Polypeptides having binding affinity for her2 |
| 04/05/2006 | EP1641794A1 Novel pyrrolodihydroisoquinolines useful in the treatment of cancer |
| 04/05/2006 | EP1641792A1 Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 04/05/2006 | EP1641791A1 3-(guanidinocarbonyl)heterocycle derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions including them |
| 04/05/2006 | EP1641789A2 Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof |
| 04/05/2006 | EP1641777A1 Indole derivatives with apoptosis-inducing effect |
| 04/05/2006 | EP1641774A1 Pentafluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators |
| 04/05/2006 | EP1641767A2 Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing the same |
| 04/05/2006 | EP1641759A2 Malonamide derivatives |
| 04/05/2006 | EP1641755A1 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl)piperidine as glucosylceramide synthase (gcs) inhibitor |
| 04/05/2006 | EP1641478A1 Herbal compositions for the treatment and prevention of prostate disorders |
| 04/05/2006 | EP1641474A1 Therapeutical composition containing dentritic cells and use thereof |
| 04/05/2006 | EP1641467A1 (20s)-1alpha-hydroxy-2-methylene-19-nor-vitamin d3 and its uses |
| 04/05/2006 | EP1641466A1 2-methylene-19-nor-20(s)-25-methyl-1alpha-hydroxycalciferol and its uses |
| 04/05/2006 | EP1641460A2 Stable 5, 10-methylene-tetrahydrofolate pharmaceutical compounds |
| 04/05/2006 | EP1641457A1 Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| 04/05/2006 | EP1641455A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 04/05/2006 | EP1641454A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 04/05/2006 | EP1641453A2 Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent |
| 04/05/2006 | EP1641449A1 Cancer treatment with epothilones |